These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 21751810)

  • 1. Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.
    Su J; Chen F; Cryns VL; Messersmith PB
    J Am Chem Soc; 2011 Aug; 133(31):11850-3. PubMed ID: 21751810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor extracellular acidity activated "off-on" release of bortezomib from a biocompatible dendrimer.
    Wang M; Wang Y; Hu K; Shao N; Cheng Y
    Biomater Sci; 2015 Mar; 3(3):480-9. PubMed ID: 26222291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boronate-crosslinked polysaccharide conjugates for pH-responsive and targeted drug delivery.
    Zhang YH; Zhang YM; Yu J; Wang J; Liu Y
    Chem Commun (Camb); 2019 Jan; 55(8):1164-1167. PubMed ID: 30632564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery.
    Liu S; Ono RJ; Yang C; Gao S; Ming Tan JY; Hedrick JL; Yang YY
    ACS Appl Mater Interfaces; 2018 Jun; 10(23):19355-19364. PubMed ID: 29757607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of pH-Active Catechol-Bearing Polymeric Nanogels with Glutathione-Responsive Dissociation to Codeliver Bortezomib and Doxorubicin for the Synergistic Therapy of Cancer.
    Qiu Y; Bai J; Feng Y; Shi X; Zhao X
    ACS Appl Mater Interfaces; 2021 Aug; 13(31):36926-36937. PubMed ID: 34319074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
    Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
    Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
    Sak K
    Curr Cancer Drug Targets; 2022; 22(9):741-748. PubMed ID: 35578889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug release and kinetic models of anticancer drug (BTZ) from a pH-responsive alginate polydopamine hydrogel: Towards cancer chemotherapy.
    Rezk AI; Obiweluozor FO; Choukrani G; Park CH; Kim CS
    Int J Biol Macromol; 2019 Dec; 141():388-400. PubMed ID: 31493453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH/sugar dual responsive core-cross-linked PIC micelles for enhanced intracellular protein delivery.
    Ren J; Zhang Y; Zhang J; Gao H; Liu G; Ma R; An Y; Kong D; Shi L
    Biomacromolecules; 2013 Oct; 14(10):3434-43. PubMed ID: 24063314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy.
    Li D; Su T; Ma L; Yin F; Xu W; Ding J; Li Z
    Eur J Med Chem; 2020 Aug; 199():112367. PubMed ID: 32474350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
    Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
    ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
    Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
    Min J; Moon H; Yang HJ; Shin HH; Hong SY; Kang S
    Macromol Biosci; 2014 Apr; 14(4):557-64. PubMed ID: 24847525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An implantable smart magnetic nanofiber device for endoscopic hyperthermia treatment and tumor-triggered controlled drug release.
    Sasikala ARK; Unnithan AR; Yun YH; Park CH; Kim CS
    Acta Biomater; 2016 Feb; 31():122-133. PubMed ID: 26687978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic multifunctional biodegradable polymers for pH- and ROS-responsive anticancer drug delivery.
    Su M; Xiao S; Shu M; Lu Y; Zeng Q; Xie J; Jiang Z; Liu J
    Colloids Surf B Biointerfaces; 2020 Sep; 193():111067. PubMed ID: 32388121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro evaluation of a pH-sensitive PLA-PEG-folate based polymeric micelle for controlled delivery of docetaxel.
    Hami Z; Amini M; Ghazi-Khansari M; Rezayat SM; Gilani K
    Colloids Surf B Biointerfaces; 2014 Apr; 116():309-17. PubMed ID: 24503352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeting, pH-responsive, and stable unimolecular micelles as drug nanocarriers for targeted cancer therapy.
    Yang X; Grailer JJ; Pilla S; Steeber DA; Gong S
    Bioconjug Chem; 2010 Mar; 21(3):496-504. PubMed ID: 20163170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-responsive robust polymer micelles with metal-ligand coordinated core cross-links.
    Hwang GH; Min KH; Lee HJ; Nam HY; Choi GH; Kim BJ; Jeong SY; Lee SC
    Chem Commun (Camb); 2014 Apr; 50(33):4351-3. PubMed ID: 24643304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.